Clinical Trials Results
Results for the search you initiated will be displayed below.
-
Click here for details...
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin
and how well it works when given with frontline chemotherapy in treating patients with newly
diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab
ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used
in chemotherapy work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute
lymphoblastic leukemia.
-
Click here for details...
This phase II/III trial studies how well daunorubicin and cytarabine with or without
uproleselan works in treating older adult patients with acute myeloid leukemia receiving
intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may
prevent cancer from returning or getting worse. Giving daunorubicin and cytarabine with
uproleselan may work better in treating patients with acute myeloid leukemia compared to
daunorubicin and cytarabine alone.
-
Click here for details...
This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the
usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell
lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab,
linked to a drug, called CalichDMH. Inotuzumab is a form of targeted therapy because it
attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22
receptors, and delivers CalichDMH to kill them. Chemotherapy drugs work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may help
shrink the cancer and stop it from returning.
-
Click here for details...
This phase Ib/II clinical trial studies the side effects and best dose of venetoclax and how
well it works when given together with vincristine liposomal in treating patients with T-cell
or B-cell acute lymphoblastic leukemia that has come back or does not respond to treatment.
Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Drugs used in chemotherapy, such as vincristine liposomal, work in different
ways to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving venetoclax together with vincristine
liposomal may work better in treating patients with acute lymphoblastic leukemia.
-
Click here for details...
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or
nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of
minimal residual disease, defined as the levels of a gene product called bcr-abl in the
blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer
cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and
dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic
myeloid leukemia.
-
Click here for details...
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will
effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment
with chemotherapy.
-
Click here for details...
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute
lymphoblastic leukemia that has come back (relapsed) or does not response to treatment
(refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop
the growth of cancer cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
-
Click here for details...
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed
treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic
lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Starting treatment with the
venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes
for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to
starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
|